

## OMNIINSIGHT™ CORONARY ARTERY DISEASE PROGRAM

A comprehensive, MENA-focused approach integrating **polygenic risk scores (PRS)**, **monogenic variant testing**, **clinical factors**, and **lifestyle** to deliver individualized coronary artery disease prevention strategies.

### WHY PRS MATTERS

- Traditional genetic testing **alone is not enough**.
- PRS modulates the penetrance of **single-gene mutations**, meaning two patients with the same variant may have very different levels of risk.
- Uses a clinically validated multi-ancestry PRS, calibrated for diverse populations including **the MENA region**.



### PERSONALIZED PREVENTION

Results are translated into **a clinically actionable care plan** aligned with best-practice guidelines, enabling personalized recommendations for **screening, lifestyle modification, medical interventions, and genetic counseling**.



## MONOGENIC RISK COVERAGE

Monogenic Risk Coverage identifies high-impact pathogenic variants across **NCCN** recommended genes, including: **LDLR, APOB, PCSK9, LDLRAP1**.



## POWERED BY BLENDED GENOME EXOME

The innovative genomic technology is developed in collaboration **with Broad Clinical Labs at Harvard and MIT**, the program combines **95.5x Whole-Exome Sequencing (WES)** with **genome-wide IcWGS** to detect both rare mutations and polygenic risk with high precision.

Testing is performed through **CAP/CLIA-accredited laboratories**, with analytics support from **Allelica**, (MGB/LMM), and regional collaboration with **Novo Genomics**.  
**Equipped with most precise risk assessment available.**



Get started today  
[info@avigena.com](mailto:info@avigena.com)  
+1 617 412 5580